Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | NPC1 | O15118 | 2/20 | 0.78 |
| ▸ | RAB9A | P51151 | 2/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.59 |
| ▸ | RXRA | P19793 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4469127 | 0.95 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| Hydrochloric Acid SCHEMBL11150354 | 0.90 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL6811211 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL7047105 | 0.88 | SMN1; SMN2 (0.80) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL6453697 | 0.86 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL31194744 | 0.86 | NPC1 (0.78) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL1119481 | 0.86 | NPC1 (0.78) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL6246974 | 0.86 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL4278415 | 0.86 | NPC1 (0.73) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 | |
| SCHEMBL242563 | 0.86 | MRGPRX4 (0.77) | SMN1; SMN2NPC1RAB9AHPGDSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111253385-B | Heterocyclic compound, preparation method and application | 遵义医科大学珠海校区 | 2023-11-24 | — | — | CN | disclosed |
| CN-109134451-A | 1,3- 2-substituted carbamide class and thiourea derivatives and its application | 遵义医学院 | 2019-01-04 | — | — | CN | disclosed |
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | disclosed |
| EP-2593435-B1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | TAIRX INC (TW) | 2016-09-07 | — | — | EP | disclosed |
| CN-103347859-B | Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives | EFFICIENT PHARMA MANAGEMENT CORP. (CN) | 2015-12-02 | — | — | CN | disclosed |
| CN-103347859-A | Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives | EFFICIENT PHARMA MAN CORP | 2013-10-09 | — | — | CN | disclosed |
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| EP-2593435-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2013-05-22 | — | — | EP | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009519-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | EFFICIENT PHARMA MANAGEMENT CORP. (TW) | 2012-01-19 | — | — | WO | disclosed |
| EP-0888310-B1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | EP | disclosed |
| US-6887874-B2 | Cinnoline compounds | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| US-20030212055-A1 | Cinnoline compounds | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| US-20030199513-A1 | Cinnoline derivatives and use as medicine | ZENECA LIMITED | 2003-10-23 | — | — | US | disclosed |
| CN-1446214-A | Cinnoline compounds | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | CN | disclosed |
| EP-1309587-A1 | CINNOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| US-6514971-B1 | For use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans | ZENECA LIMITED (GB) | 2003-02-04 | — | — | US | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-0888310-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034876-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199513-A1 | Cinnoline derivatives and use as medicine | VEGFA, CNR1, CCR7 | SMN1; SMN2 2268/4885NPC1 338/4885RAB9A 1455/4885 |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | SMN1; SMN2 3441/4885NPC1 874/4885RAB9A 546/4885 |
| US-20030212055-A1 | Cinnoline compounds | VEGFA, PGF, CCR7 | SMN1; SMN2 2554/4885NPC1 968/4885RAB9A 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.